
Opinion|Videos|April 19, 2024
NSCLC: Molecular Testing in the Metastatic Setting
The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Advertisement
Episodes in this series

Advertisement
Related to this article

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.

An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.

The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in HER2+ Breast Cancer
2
FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC
3
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
4
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
5


